DXC006 / Hangzhou DAC Biotech - LARVOL DELTA

DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial. (ASCO 2026) - P1 | "DXC006 demonstrated a manageable safety profile and adequate tolerability, and showed encouraging efficacy in pretreated advanced solid tumors, especially in SCLC. Clinical trial information: NCT06224855. Research sponsor: Hangzhou DAC Biotechnology Co., Ltd."

ADC • Clinical • First-in-human • Metastases • P1 data • Endocrine Cancer • Hematological Disorders • Interstitial Lung Disease • Lung Adenocarcinoma • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Neoplasm • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • NCAM1

"Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. (PubMed, Cancer Discov) - "The treatment arsenal for small cell lung cancer could soon include antibody-drug conjugates, with early data from three phase I studies indicating robust response rates to CD56-targeting DXC006, DLL-3-targeting BL-M14D1, and B7-H3-targeting SYS6043. The latter also appears active in other tumor types, including ovarian and breast cancers. As well, phase II findings on a fourth ADC candidate, HER2-targeting trastuzumab brengitecan, suggest its strong efficacy in platinum-resistant ovarian cancer."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3 • HER-2 • NCAM1

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd. | N=110 ➔ 280 | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Jun 2027

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase Ib/II Study of DXC006 for Injection in Combination With Immune Checkpoint Inhibitors or Platinum-Based Agents for Small Cell Lung Cancer. (clinicaltrials.gov) - P1/2 | N=200 | Not yet recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd.

Checkpoint inhibition • New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies (AACR 2024) - "Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal nonoverlapping epitopes. mAbs 2016; 799-810."

ADC • PK/PD data • Preclinical • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroblastoma • Oncology • Small Cell Lung Cancer • Solid Tumor • NCAM1

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd.

Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor